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Lisenka E.L.M. Vissers,1 Bjo¨rn Menten,3 Michael W. Collard,2,15 and Bert B.A. de Vries1,15,*
Recently, we identified in two individuals with intellectual disability (ID) different de novo mutations in DEAF1, which encodes a tran-
scription factor with an important role in embryonic development. To ascertain whether these mutations inDEAF1 are causative for the
ID phenotype, we performed targeted resequencing ofDEAF1 in an additional cohort of over 2,300 individuals with unexplained ID and
identified two additional individuals with de novo mutations in this gene. All four individuals had severe ID with severely affected
speech development, and three showed severe behavioral problems. DEAF1 is highly expressed in the CNS, especially during early em-
bryonic development. All four mutations were missense mutations affecting the SAND domain of DEAF1. Altered DEAF1 harboring any
of the four amino acid changes showed impaired transcriptional regulation of theDEAF1 promoter. Moreover, behavioral studies inmice
with a conditional knockout ofDeaf1 in the brain showedmemory deficits and increased anxiety-like behavior. Our results demonstrate
that mutations in DEAF1 cause ID and behavioral problems, most likely as a result of impaired transcriptional regulation by DEAF1.Introduction
Intellectual disability (ID) is a highly heterogeneous disor-
der that is frequently caused by de novo gene muta-
tions.1–4 Hence, exome sequencing of the individuals
involved and their parents (trio approach) is an effective
way of identifying the underlying cause. Recently, we
and others showed that in 16%–31% of individuals with
ID, mutations in genes associated with ID could be identi-
fied via trio-based exome sequencing.1,2,4,5 In an addi-
tional ~20% of these individuals, a de novo mutation
was identified in a candidate gene that was not previously
associated with ID.1,2,4 For these candidate genes associ-
ated with ID, it is often difficult to determine whether
the de novo mutation is causative for the ID phenotype.
To establish their role in an ID phenotype, it is essential
to identify other individuals with both de novo mutations
in the same gene and a similar phenotype and/or to
perform functional assays to assess the effect of the amino
acid change on the respective protein. For one of these1Department of Human Genetics, Radboud University Medical Center, 6500
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The Amcandidate genes, DEAF1 transcription factor (DEAF1
[MIM 602635; RefSeq accession number NM_021008.2]),
de novo mutations were identified in two independent
studies in two unrelated individuals with severe ID.2,4
DEAF1 encodes deformed epidermal autoregulatory fac-
tor 1 homolog (DEAF1), a transcription factor that binds
to TTCG motifs in DNA.6 It is involved in the regulation
of various genes,7 including itself, as both a transcriptional
activator8–10 and a repressor.11,12 DEAF1 comprises multi-
ple structural domains: a SAND (Sp-100, AIRE, NucP41/
75, andDEAF1) domain,which is essential forDNAbinding
(via its KDWK motif) and protein-protein interac-
tions;11,13,14 a MYND (myeloid translocation protein 8,
Nervy, and DEAF1) domain, which is a cysteine-rich
module also involved in protein-protein interactions;15,16
and a nuclear localization signal and a nuclear export signal
important for nuclear localization of DEAF1.6 A region
within the nuclear export signal and another in the
SANDdomain alsomediate DEAF1multimerization, which
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animal models produces neural-tube defects in mice18 and
early embryonic arrest in Drosophila.19 In humans, DEAF1
has previously been associated with major depression and
suicide,20–22 autoimmune disorders,7 and cancer.8,23
Here, we aimed to determine whether de novo muta-
tions affecting the SAND domain of DEAF1 could be the
underlying cause of ID in humans by (1) identifying and
deeply phenotyping multiple individuals with de novo
mutations in DEAF1, (2) assessing the effect of the human
amino acid substitutions on DEAF1 function, and (3)
studying the phenotypic effect of the disruption of Deaf1
in a mouse model. The results show that mutations
affecting the SAND domain of the transcription factor
DEAF1 might lead to ID with severely affected expressive
speech and behavioral abnormalities.Subjects and Methods
Identification of Individuals with DEAF1 Mutations
Targeted resequencing of the coding sequence of DEAF1 was
performed in two cohorts of individuals with unexplained ID.
The first cohort of 765 individuals was resequenced after tar-
geted array-based enrichment as described before,1 whereas the
second cohort of 1,561 individuals was assayed with molecular
inversion probes (MIPs) as described previously.24 Both of these
cohorts were selected from the in-house collection of the
Department of Human Genetics of Radboud University Medical
Center (Nijmegen) and consisted of over 5,000 samples from
individuals with unexplained ID. Candidate mutations were
tested by standard Sanger sequencing approaches on DNA ex-
tracted from peripheral blood. For assessing the de novo occur-
rence of confirmed mutations, DNA from the parents was tested.
This study was approved by the institutional review board
Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen
NL36191.091.11. Written informed consent was obtained from
all individuals.Assessment of DEAF1 Expression
DEAF1 expression was assessed in different human fetal and adult
tissues and in mouse brain by quantitative PCR (qPCR). In addi-
tion, the expression of the DEAF1 orthologs deaf1-a (zgc:194895)
and deaf1-b (zgc:171506) in zebrafish was assessed by in situ hy-
bridization and qPCR at different time points.Assessment of Altered DEAF1
Plasmids and Site-Directed Mutagenesis
DEAF1 mammalian expression plasmids in pcDNA3 and fused in-
frame to a carboxy-terminal FLAG epitope tag were derived from
the human DEAF1 cDNA (GenBank accession number AF049459)
and have been previously described.11,15 Site-directedmutagenesis
to introduce the p.Arg224Trp (c.670C>T), p.Ile228Ser (c.683T>G),
p.Gln264Pro (c.791A>C), andp.Arg254Ser (c.762A>C) amino acid
substitutions into the DEAF1 expression plasmids were generated
by PCR using primers containing the indicated human amino
acid substitutions. Primers also contained specificDEAF1 native re-
striction endonuclease sites to facilitate subcloning. Digested PCR
fragments were used to replace the corresponding regions of
wild-type (WT)DEAF1. The reporter plasmid pDEAF1pro-luciferase
is similar to the previously described pNUDRproCAT611 and was650 The American Journal of Human Genetics 94, 649–661, May 1, 2constructedby subcloningof the 1,150bp region50 to theATGstart
codon of the human DEAF1 promoter into the pGL3 basic firefly
luciferase reporter plasmid (Promega). The mouse Eif4g3 promoter
region from609 toþ58 (relative to the transcription start site)was
amplified from mouse genomic DNA by PCR (primers are in Table
S1, available online), and the product was subcloned into the NheI
and HindIII sites of the pGL3 basic plasmid. All plasmid constructs
were confirmed by DNA sequencing by a Beckman Coulter CEQ
8000 Genetic Analysis System.
Transcription Assay
Human embryonic kidney 293T (HEK293T) cells were plated in
24-well plates (90,000 cells per well) and transfected with 125 ng
pcDNA3 (control) or DEAF1 (expressing WT or altered DEAF1)
expression plasmids, along with 375 ng pDEAF1pro-luciferase or
pEif4g3pro-luciferase and 1.25 ng Rous sarcoma virus (RSV)-
Renilla (for normalization), via the calcium phosphate technique.
Media were replaced 18 hr later, and luciferase assays were per-
formed 24 hr later with the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s protocol.
Purification of Recombinant FLAG-Tagged Proteins
HEK293T cells were transfected with 10 mg of expression plasmids
for WT or altered FLAG-tagged DEAF1. Cell lysates were prepared
in lysis buffer P (150 mM NaCl, 50 mM Tris, pH 7.5, 1 mM
EDTA, 1% Triton X-100, 1 mMDTT, 1mMNaF, and Complete Pro-
tease Inhibitor Cocktail [Roche]) on ice, and cell debris were
removed by centrifugation. Lysates were incubated with anti-
FLAG beads overnight at 4C. Proteins bound to the beads were
washed four times with lysis buffer P and once with Tris-buffered
saline (TBS: 50 mM Tris, pH 7.4, and 150 mMNaCl) before elution
with 200 ng/ml FLAG in TBS for 30 min on ice and then the addi-
tion of glycerol to 50%. Protein concentrations were calculated by
Coomassie blue staining and comparison to BSA standards after
SDS-PAGE (Figure S1). Band intensities were quantified on a Li-
Cor Odyssey CLx.
GST Pull-downs to Examine DEAF1 and XRCC6 Interactions
Glutathione S-transferase (GST) and GST-XRCC6 fusion proteins
were purified as previously described.14 FLAG-tagged WT and
altered DEAF1were purified from transfected HEK293Tcells as pre-
viously described (see above and Jensik et al.14). Five hundred
nanograms of GST or GST-XRCC6 attached to glutathione beads
was incubated with 100 ng of purified WT or altered FLAG-tagged
DEAF1 in interaction buffer (50 mM NaCl, 20 mM Tris, pH 7.9,
0.1% Nonidet P-40, 10% glycerol, 1 mM dithiothreitol, and
0.25% BSA) overnight at 4C. Beads were then washed six times
with interaction buffer, and proteins were eluted from beads
with Laemmli sample buffer. Eluted samples and similar amounts
of purified FLAG-tagged DEAF1 used in the GST pull-down
(inputs) were separated on SDS-PAGE gels and transferred to poly-
vinylidene fluoride membrane. Immunoblot analysis was then
performed with an anti-DEAF1 antibody.6
Electrophoretic Mobility Shift Assays
For electrophoretic mobility shift assays (EMSAs), we used full-
length recombinant DEAF1 isolated from HEK293 cells (Figure S1)
and two DNA ligands for DEAF1—the first consisted of two TTCG
motifs spaced by 11 nucleotides and was based on a sequence
found in the human DEAF1 promoter,11,12 and the second had
two TTCG motifs spaced by 6 nucleotides. This latter sequence
was a high-affinity ligand and was based on the preferred binding
motif of DEAF1 (data not shown). Fluorescently labeled double-
stranded DNA (dsDNA) probes with 11 or 6 bp spacing of CG
dinucleotides were generated by hybridization of oligonucleo-
tides N52-69F and N52-69R or S6conF and S6conR, respectively014
(Table S1). Oligonucleotides were labeled at their 50 ends with
IRDye800 (N52-69) or IRDye700 (S6con) and purified by high-per-
formance liquid chromatography (Integrated DNA Technologies).
WT and altered FLAG-tagged DEAF1 from HEK293T cells
(850 fmol) were incubated with 500 fmol of dsDNA probe and
1 mg of poly(dA-dT) (nonspecific competitor) in a 20 ml reaction
containing 70 mM KCl, 35 mM Tris, pH 7.5, 0.7 mM DTT, 1 mM
MnSO4, 2% (v/v) glycerol, and 100 U of lambda protein phospha-
tase (New England Biolabs) for 20 min at 25C. Protein-DNA
complexes were separated as previously described,11 and band in-
tensities were quantified on a Li-Cor Odyssey CLx.
Subcellular Localization
HEK293T cells on 35 mm dishes were cotransfected with 500 ng
of expression plasmids for WT or altered FLAG-tagged DEAF1
and 500 ng pcDNA3 or hemagglutinin (HA)-tagged p.Lys304Thr
DEAF1 expression plasmids via the calcium phosphate technique.
Twenty-four hours later, cells were fixed in paraformaldehyde,
permeabilized in methanol, and incubated with rabbit anti-
HA (1:1,000 Santa Cruz) and mouse anti-FLAG (1:1,000 Sigma
Aldrich) antibodies followed by Alexafluor-488-conjugated goat
anti-rabbit IgG and Cy3-conjugated donkey anti-mouse IgG. Cells
were visualized with an Olympus BW50 fluorescence microscope
with a 603 water objective.Generation of Mouse Knockout Models for Deaf1
Mice with a targeted disruption of exons 2–5 of Deaf1 (Deaf1þ/
mice) were produced (Figure S3) and then backcrossed onto a
C57BL/6 background for seven generations before F1 crosses were
performed. In addition, a conditional knockout of Deaf1 in mouse
brainwas producedwithmicewith loxP sites flanking exons 2–5 of
Deaf1 (‘‘floxed,’’Deaf1þ/flmice) (Figure S3). Thesewere bred to con-
genic status onto a C57BL/6 background and were then bred to
mice transgenic for nestin-cre (Nes-cre); these latter mice express
Cre recombinase in neuronal and glial precursors by embryonic
day 11.25 Subsequent breeding produced mice with the genotype
Deaf1fl/fl;Nes-cre, resulting in neuronal homozygous knockout
(NKO) of Deaf1 (these mice are hereafter referred to as NKO
mice). Mice with a single conditional Deaf1 allele and positive for
Nes-cre have the genotypeDeaf1þ/fl;Nes-cre. Mice with any combina-
tion ofWTor floxedDeaf1 alleles but lackingNes-cre are referred to
as control mice. Detailed protocols and supporting data for these
procedures are provided in the Supplemental Data.Phenotyping of Mice with Conditional Targeting of
Deaf1
Mice were tested for anxiety with the elevated plus maze (EPM)
and the open-field test. The EPM tests for an animal’s conflict be-
tween exploration and fear of open and/or elevated places. The
EPM consists of two opposed closed arms (44 3 6 cm) with raised
walls (18 cm high) crossing with two open arms (44 3 6 cm)
without walls. A central platform (6 3 6 cm) links the open and
closed arms. The apparatus is elevated to a height of 55 cm from
the floor. A mouse is placed in the central platform and allowed
to explore the maze for 5 min, and movements are recorded
with a digital camera and computer and analyzed with the ANY-
maze software program (San Diego Instruments) for time spent
and distance traveled. Open-field exploration also tests for uncon-
ditioned behavior and is designed to evaluate the total amount
and rate of movement and the type of spontaneous activity and
to provide a partially specific measure of anxiety-related behavior.
The equipment consists of an open box (58 3 58 cm), and theThe Amanimal is placed in the central arena, from which it is free to
explore the box for 5 min. Mice prefer to stay near the walls of
the box and avoid the center zone, which induces the conflict.
Reduced time spent and distance traveled in the center zone is
indicative of increased anxiety-like behavior in mice. Paths were
recorded and analyzed with ANY-maze software.
The EPM and the open-field test were performed from 10 a.m.
to 3 p.m. with constant illumination (50 lux). Between animals,
testing surfaces were wiped with 70% ethanol followed by distilled
water and then dried completely.
Learning and memory were tested with the Morris water maze
and fear-conditioning tests. A white, circular tank 1 m in diameter
and 30 cm deep was filled with 22C –24C water to a depth of
20 cm. Mice were tested in the water maze for 9 days. The animals
were first trained for three trials per day for 3 days with a visible
escape platform raised 1 cm above the water line. The interval be-
tween each trial was approximately 1 hr. On the fourth training
day, the platform was moved to the opposite quadrant of the
pool and submerged 1 cm below the surface of the water. The
mice were given 5 days of hidden platform training, as well as
three trials per day with a 1 hr intertrial interval. A 1 minute probe
trial, with the platform removed from the pool, was given 7 days
after the last hidden-platform trial. For both visible- and hidden-
platform training, every trial began from a different starting posi-
tion, and the mouse was placed in a beaker facing the wall of the
tank. If the mouse did not locate the platform within the allotted
time, it was placed on the platform by the experimenter. Mice were
left on the platform for 30 s at the end of each trial before being
removed from the tank with a large metal spoon and placed under
a heat lamp for 5–10 min before being returned to their home
cages for 1 hour before the next trial. Swim times and distances
during training, as well as probe-trial parameters, were collected
with ANY-maze software. Statistical analysis was performed with
a two-way repeated-measures ANOVA (genotype3 trials) followed
by a Bonferroni posttest to analyze escape latencies in visible- and
hidden-platform testing. A two-way ANOVA (genotype 3 quad-
rants) followed by a Bonferroni posttest was used to analyze the
time spent in each quadrant during the first trial of hidden-plat-
form testing and for the probe trial. For fear conditioning, mice
were placed on the first day in a test chamber (30.5 cm length 3
24.1 cm width3 21.0 cm height, StandardModular Test Chamber
ENV-008, Med Associates) for a conditioning session of 4 min 90 s
of habituation, a 2 s foot shock (0.5 mA), 90 s of no stimuli,
another foot shock, and a final 60 s of no stimuli. Twenty-four
hours after the conditioning session, mice were placed in the
test chamber again for 5 min for testing contextual fear condition-
ing. The percentage of time spent freezing was quantified by video
image analysis (Freeze Frame, Coulbourne Instruments) and
ANOVA. After the fear-conditioning test, foot-shock-sensitivity
testing was performed as outlined in Figure S9.
Depression-related behavior was tested by sucrose preference
(a test for anhedonia) and the forced swim test, whereas balance
and mobility were tested by an accelerating-rotarod test. Detailed
methodology of these three tests is provided in Figure S7.Results
Individuals with De Novo Mutations in DEAF1
Upon the identification of two separate de novomutations
inDEAF1 by trio-based exome sequencing in two indepen-
dent cohorts encompassing 10 and 51 individuals witherican Journal of Human Genetics 94, 649–661, May 1, 2014 651
Table 1. Molecular and Clinical Details of Individuals with DEAF1 Mutations
Molecular and Clinical
Details Individual 14 Individual 22 Individual 3 Individual 4
Gender male female male female
Age at last visit 9 years 7 years 10 years 10 years
Parental age mother, 32 years
father, 35 years
mother, 31 years
father, 32 years
mother, 29 years
father, 30 years
mother, 40 years
father, 48 years
Mutations
Amino acid changea p.Ile228Ser p.Gln264Pro p.Arg224Trp p.Arg254Ser
cDNA changeb c.683T>G c.791A>C c.670C>T c.762A>C
Chromosome positionc chr11: 686,979 chr11: 686,871 chr11: 686,992 chr11: 686,900
PhyloP26 4.4 2.5 3.4 0.4d
SNPs&GO27 disease related disease related disease related disease related
MutPred28 0.825 0.659 0.551 0.539
PolyPhen-229 0.984 0.972 0.996 0.999
Growth
Birth weight (g) 2 SDs 0.5 SD þ0.7 SD NR
Height (cm) 1.3 SDs 0.6 SD 0.4 SD 1.7 SDs
Weight (kg) þ0.5 SD 1.5 SDs 0.8 SD 0 SD
Head circumference (cm) 0.6 SD þ0.1 SD 1 SD þ0.3 SD
Development
Motor delay mild mild mild mild
Expressive speeche absent ten single words absent disappeared at 18 months
Intellectual disability severe moderate severe severe
Regression   þ þ
Neurological
Contact poor eye contact good poor eye contact poor eye contact
Hypotonia  þ  
Behavioral problems þ  þ þ
Autism þ  þ þ
Mood swings þ  þ þ
Fascinations þ NR NR þ
High pain threshold þ in childhood þ þ
Sleeping problems   þ þ
Abnormal walking pattern þ þ þ þ
Abnormal brain MRI NR   þ
Facial
Thin and/or fair hair þ þ  þ
Straight eyebrows þ þ þ þ
Full nasal tip þ þ þ þ
Cupid’s bow in upper lip  þ þ þ
Full lower lip þ þ  þ
(Continued on next page)
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Table 1. Continued
Molecular and Clinical
Details Individual 14 Individual 22 Individual 3 Individual 4
Prominent chin þ  þ þ
Other upslant, epicanthic folds frontal bossing, high palate brachycephaly, widow’s peak,
flat face
NR
Extremities
Fetal finger pads þ  þ 
Skin syndactyly in toes 2
and 3
þ þ þ 
Hyperlaxity þ þ  
Other
Recurrent infections in childhood þ þ in childhood
Sacral dimple  þ þ 
Other clinical features scrotal raphe, flat feet sandal gap 20–40 dB hearing loss,
clinodactyly in toes 3 and 4,
dry skin
clinodactyly in toes 4 and 5
Other detected gene
mutations
NR DOCK9 c.1604C>T
(p.Ala535Val) and CDK18
c.118C>T (p.Arg40Trp)
SCN2A c.1570C>T
(p.Arg524*)
NR
The following abbreviation is used: NR, not reported.
aRefSeq NP_066288.
bRefSeq NM_021008.2.
cUCSC Genome Browser hg19.
dThis base is the third base of a codon.
eSpeech comprehension was significantly better in all four individuals.severe ID,2,4 we performed targeted resequencing of
DEAF1 in an additional cohort of over 2,300 individuals
with ID. Here, we identified two additional individuals
with a de novo mutation in DEAF1, resulting in a total
of four individuals with de novo mutations in this
gene: c.683T>G (p.Ile228Ser), c.791A>C (p.Gln264Pro),
c.670C>T (p.Arg224Trp), and c.762A>C (p.Arg254Ser)
(Table 1, Figures 1A and 1B). All children (age range 7–10
years) showed moderate to severe ID with severely affected
expressive speech and only mild motor delay (Table 1).
All had a happy predisposition, but three had severe
behavioral problems consisting of autistic, hyperactive,
compulsive, and aggressive behavior with striking mood
swings. Other frequently observed abnormalities were
recurrent infections, a high pain threshold, and an
abnormal walking pattern. All had normal body measure-
ments, only mild dysmorphism (Figure 1A), and no further
congenital anomalies.
DEAF1 mRNA Expression
qPCR analysis ofDEAF1mRNA in various human fetal and
adult tissues showed that DEAF1 was expressed more than
30 times higher in fetal and adult brain than in the duo-
denum (Figure S2C). In addition, qPCR analysis of Deaf1
mRNA expression in the brain of adult mice showed that
Deaf1was expressed 5–203 higher in various brain regions
than in the liver (Figure S5). Therefore, we used in situ
hybridization at various embryonic stages of zebrafish toThe Amstudy the expression pattern of deaf1-a and deaf1-b, which
share 53% and 36% homology, respectively, with human
DEAF1. This showed the highest expression in the brain
and spinal cord of both orthologs (Figure S2A). Expression
quantification by qPCR showed that deaf1-a was tran-
siently expressed about three times higher at 24 days post-
fertilization (dpf) than at 14 dpf (Figure S2B), whereas
expression of deaf1-b was very low to absent at all embry-
onic stages (data not shown).
Functional Consequences of DEAF1 Mutations
All four de novomutations found in these individuals were
missense mutations affecting evolutionary conserved
amino acids within the SAND domain (Figures 1C and
1D) and were predicted by SNPs&GO,27 MutPred,28 and
PolyPhen-229 to be detrimental to protein function
(Table 1). None of these mutations were present in dbSNP
v.139, the NHLBI Exome Sequencing Project Exome
Variant Server, or our in-house database containing exome
data of over 2,000 individuals. In silico modeling by
Project HOPE (Have Your Protein Explained)30 with the
mouse putative nuclear protein ortholog (SP110 [Protein
Data Bank ID 1UFN], which shares 40% homology with
the human DEAF1 SAND domain) as a template predicted
that all four amino acid substitutions might affect SAND
domain function either by directly interfering with the
DNA-interaction surface or by disturbing the core structure
of this domain (Figure 2A). Therefore, we compared theerican Journal of Human Genetics 94, 649–661, May 1, 2014 653
Figure 1. Individuals with DEAF1 Mutations
(A) Frontal and lateral photographs of individuals with de novo mutations in DEAF1. Only mild facial dysmorphisms were observed.
(B) Sanger sequencing chromatograms showing the DEAF1 mutations in the proband (top panel), but not in the parents (bottom
panels).
(C) Schematic overview of DEAF1, including the known domains (SAND domain, zinc-finger homology [ZnF] domain, nuclear locali-
zation signal [NLS], nuclear export signal [NES], and MYND domain). The positions of the four identified missense substitutions
(p.Arg224Trp [p. R224W], p.Ile228Ser [p.I228S], p.Arg254Ser [p.R254S], and p.Gln264Pro [p.Q264P]) in the SAND domain are depicted.
(D) Multispecies alignment of the SAND domain in eukaryotes. Amino acid residues with substitutions are indicated by arrows. Amino
acids with similar properties aremarked in green, and dissimilar amino acids aremarked in red. Zebrafish ‘‘a’’ is zgc:194895, and zebrafish
‘‘b’’ is zgc:171506.functional activities of WT DEAF1 and of altered DEAF1
harboring either of the four identified amino acid substitu-
tions along with two previously described alterations
affecting the SAND domain.11
It was previously shown that DEAF1 represses its own
DEAF1 promoter and that amino acid substitutions
affecting the SAND domain can eliminate DNA binding
and promoter repression.11,12 In a reporter assay with the
human DEAF1 transcriptional promoter fused to a lucif-
erase reporter gene, overexpression of DEAF1 containing
any of the four amino acid substitutions resulted in a loss
of the ability to repress the DEAF1 promoter (Figure 2B).
A similar loss of DEAF1-promoter repression was observed
for the previously characterized combined p.Lys250Ala
and p.Lys253Ala substitutions, localized within the essen-
tial positively charged surface of the KDWKmotif, whereas
the randomly selected p.Arg226Ala change, located be-
tween the amino acid substitutions identified in this
study (p.Arg224Trp and p.Ile228Ser), had no effect on
transcriptional repression,11 indicating that the amino654 The American Journal of Human Genetics 94, 649–661, May 1, 2acid substitutions identified in this study are specifically
deleterious.
DEAF1 has also been shown to function as a tran-
scriptional activator of eukaryotic translation initiation
factor 4 gamma, 3 (Eif4g3 [RefSeq accession number
NM_172703]).8,10 Relative to basal transcription, WT
DEAF1 produced about a 2-fold activation of the mouse
Eif4g3 reporter construct, whereas the amino acid substitu-
tion identified in this study (p.Arg224Trp) showed no
activation (Figure 2C). Both amino acid substitutions
p.Ile228Ser and p.Gln264Pro showed not only loss of
transcriptional activation but also an approximate 10-
fold suppression of transcription relative to basal expres-
sion levels, whereas the amino acid substitution identified
in this study (p.Arg254Ser) and the randomly selected sub-
stitution p.Arg226Ala continued to activate Eif4g3 reporter
expression.
Because the SAND domain mediates DEAF1 DNA bind-
ing, we performed EMSAs to examine whether impaired
DNA binding could underlie the impaired transcriptional014
Figure 2. DEAF1 Mutations Alter Transcriptional Regulation
(A) This 3D model of the SAND domain is based on the homolo-
gous structure from the mouse putative nuclear protein homolog
(SP110); the four amino acid substitutions are in red, and the
essential KDWK motif is in green.
(B) DEAF1 promoter activity after transfection with either WT or
altered FLAG-tagged DEAF1. Similar to the previously character-
The Amregulation. For DEAF1, we utilized two DNA ligands, one
based on a sequence found in the human DEAF1 pro-
moter11,12 and one based on the preferred binding motif
of DEAF1 (data not shown; Table S1). Recombinant
DEAF1 containing the amino acid substitutions identified
in this study (p.Arg224Trp, p.Ile228Ser, and p.Gln264Pro)
showed a complete loss of DNA binding to both DNA
ligands, whereas p.Arg254Ser altered DEAF1 displayed a
9-fold reduction in binding of the DNA ligand with
11 bp CG-spacing and a 53-fold reduction in the DNA
ligand with 6 bp CG spacing (Figure 3A). Thus, all four of
the ID-associated mutations produce proteins with loss of
or highly reduced DNA binding.
The SAND domain of DEAF1 alsomediates DEAF1multi-
merization, which is required for DNA binding.15 We
have previously demonstrated that DEAF1-DEAF1 interac-
tions can be monitored by immunofluorescence and a
relocalization of a cytoplasmically localized p.Lys304Thr
altered DEAF1 to the nucleus.15 p.Arg224Trp, p.Ile228Ser,
p.Arg254Ser, and p.Gln264Pro altered DEAF1 showed
normal localization to the nucleus, and they were all able
to relocalize the p.Lys304Thr altered DEAF1 from the cyto-
plasm to the nucleus (Figure 3C).
The SAND domain of DEAF1 also mediates interaction
with X-ray repair cross-complementing protein 6 (XRCC6,
also called Ku70 [RefSeq NP_001275905]), which is a
subunit of the DNA-dependent protein kinase complex.14
Using GST-pull-down assays, we showed that the interac-
tion with XRCC6 was greatly reduced for both amino acid
substitutions p.Ile228Ser and p.Gln264Pro and mildly
reduced for substitution p.Arg224Trp, but XRCC6 interac-
tionwith substitutionp.Arg254Serwas retained (Figure3B),
indicating that for these substitutions, SAND domain func-
tion seems further compromised.ized combined p.Lys250Ala and p.Lys253Ala substitutions, the
substitutions identified in this study (p.Arg224Trp [p.R224W],
p.Ile228Ser [p.I228S], p.Arg254Ser [p.R254S], and p.Gln264Pro
[p.Q264P]) were unable to repress DEAF1 promoter activity. The
p.Arg226Ala (p.R226A) substitution had no effect on transcrip-
tional repression. Each bar represents the mean 5 SEM of the
normalized luciferase activity of three independent experiments
when the activity of pcDNA3 (DEAF1 promoter alone) was set to
100%. One-way ANOVA with both Dunnett’s multiple compari-
son and selected Bonferroni posttest of WT DEAF1 versus each
mutant, ***p < 0.001.
(C) Promoter activity ofmouse Eif4g3 after transfectionwith either
WTor altered FLAG-tagged DEAF1. Relative to basal transcription,
WTDEAF1 andp.Arg254Ser alteredDEAF1produced about a 2-fold
activation of the reporter construct, whereas the p.Arg224Trp
altered DEAF1 showed no activation. Both the p.Ile228Ser and
the p.Gln264Pro proteins showed not only a loss of transcriptional
activation but also an approximately 10-fold suppression of tran-
scription relative to basal expression levels. The results are from
three independent experiments and analyzed as in (B). **p < 0.01.
(D) Immunoblot analysis for transfected amounts of FLAG-tagged
DEAF1 inHEK293Tcells. Equal quantities of transfected cell lysates
were assayed for WT and altered FLAG-tagged DEAF1 with the
use of anti-DEAF1 antibody (anti-actin antibody was used as a
loading control). DEAF1 amounts were similar in the transfected
cell lysates.
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Figure 3. DEAF1 Mutations Alter DNA and Protein Interactions
(A) EMSA of WT and altered FLAG-tagged DEAF1 recombinant proteins isolated from HEK293T cells. Fluorescently labeled DNA ligands
with a spacing of 11 or 6 nucleotides between the CG dinucleotides were examined. The p.Arg224Trp (p.R224W), p.Ile228Ser (p.I228S),
and p.Gln264Pro (p.Q264P) proteins lacked DNA binding, whereas the p.Arg254Ser (p.R254S) protein showed less binding than WT
DEAF1.
(B) XRCC6 interaction with recombinant FLAG-tagged DEAF1 was assessed in GST pull-downs. GST-XRCC6 could pull downWTDEAF1
and the p.Arg254Ser protein. The p.Arg224Trp protein had reduced interaction, and the p.Gln264Pro and p.Ile228Ser proteins had no
interaction. The GST-only control did not pull down DEAF1. Recombinant proteins were detected with anti-FLAG antibodies.
(C) DEAF1-DEAF1 interaction was assessed in an immunofluorescence assay. HEK293T cells were transfected with expression plasmids
for WT or altered FLAG-tagged DEAF1 by themselves or in combination with an expression plasmid for the p.Lys304Thr (p.K304T)
DEAF1 with an HA epitope tag and were then assayed for location by immunofluorescence with anti-FLAG or anti-HA antibodies.
WT and altered FLAG-tagged DEAF1localized to the nucleus. The p.Lys304Thr-HA protein localized to the cytoplasm but relocalized
to the nucleus in the presence of WT or altered DEAF1.Behavior Phenotyping of Mice with Conditional
Targeting of Deaf1
Mice with a targeted disruption of exons 2–5 of Deaf1
(Deaf1þ/ mice) were produced (Figures S3 and S4). On a
C57BL/6 background, Deaf1/ neonates died 100% of656 The American Journal of Human Genetics 94, 649–661, May 1, 2the time and Deaf1þ/ mice survived in a 2:1 ratio relative
to WT mice (Tables S2–S4), and only 3% of Deaf1/ mice
survived on a BALB/c background (Table S5), which pre-
cluded behavioral studies. Therefore, we created a condi-
tional knockout model of Deaf1 in mouse brain by014
Figure 4. Behavioral Phenotyping of Mice with Conditional Knockout of Deaf1 in the Brain
(A) Anxiety testing using the EPM. Bars represent the mean5 SEM of the time spent or distance traveled in open and closed arms (con-
trolmice, n¼ 12; NKOmice, n¼ 12). NKOmice spent significantlymore time in the closed arm and traveled significantly less distance in
the open arm. Unpaired two-tailed t test, *p < 0.05.
(B) Anxiety testing using the open-field test. Bars represent the mean5 SEM of the time spent or distance traveled in the center or wall
zones (controlmice, n¼ 12; NKOmice, n¼ 12). NKOmice displayed significantly reduced distance traveled in the center zone. Unpaired
two-tailed t test, *p < 0.05.
(C) Percentage of time freezing in response to foot shock. Training on day 1 is shown, and arrows indicate the time of a 0.5 mA
shock (control mice, n ¼ 18; Deaf1þ/fl;Nes-cre mice, n ¼ 10; NKO mice, n ¼ 14). Bars represent the mean 5 SEM. NKO mice displayed
significantly reduced freezing at 180 and 240 s. Two-way repeated-measures ANOVA with Bonferroni posttest between control and
NKO mice, ***p < 0.001.
(D) Percentage of time freezing in contextual fear conditioning. Context testing 24 hr after training is shown (control mice, n ¼ 18;
Deaf1þ/fl;Nes-cre mice, n ¼ 10; NKO mice, n ¼ 14). Bars represent the average of 5 min 5 SEM. NKO and Deaf1þ/fl;Nes-cre mice displayed
significantly reduced freezing. One-way ANOVA with Bonferroni posttest, *p < 0.05, ***p < 0.001.breeding mice with loxP sites flanking exons 2–5 of Deaf1
(Deaf1þ/fl) to mice transgenic for Nes-cre. NKO mice sur-
vived to adulthood at levels similar to those of WT mice,
and various brain regions showed 11- to 49-fold reductions
of the WT Deaf1 mRNA transcript (Figure S5).
Adult male mice (median age 4 months) consisting of
NKO, Deaf1þ/fl;Nes-cre, and control genotypes were sequen-
tially tested with two anxiety tests (the EPM and the
open-field test) followed by two tests for depression-related
behavior (the sucrose-preference test, which tests for anhe-
donia, and the forced-swim test). In addition, a second
group of adult male mice (median age 7 months) was
tested for changes in balance and mobility with an acceler-
ating-rotarod test. In anxiety tests, NKO mice spent statis-The Amtically significantly more time in the closed arms (NKO
mice ¼ 79.0% 5 3.7% versus control mice ¼ 64.7% 5
3.6%, p < 0.05) and showed less distance traveled on the
open arms of the EPM than did control mice (NKO
mice ¼ 0.34 5 0.10 m versus control mice ¼ 0.97 5
0.26 m, p < 0.05; Figure 4A). NKO mice also displayed
less distance traveled in the center zone of the open field
than did controls (NKO mice ¼ 3.125 0.38 m versus con-
trol mice ¼ 4.77 5 0.63 m, p < 0.05; Figure 4B). Distance
traveled in the closed arms of the EPM and the wall zone of
the open field was similar between the two genotypes,
indicating that the NKO mice did not have mobility defi-
ciencies. Relative to control mice, conditional heterozy-
gous mice (Deaf1þ/fl;Nes-cre) did not display any behaviorerican Journal of Human Genetics 94, 649–661, May 1, 2014 657
differences in the anxiety tests (Figure S6). No differences
were observed between NKO and control mice for
depression-like behavior in the sucrose-preference and
forced-swim tests (Figures S7A and S7B) or for rotarod per-
formance (Figure S7C).Learning and Memory in Mice with Conditional
Knockout of Deaf1
A group of adult male mice (median age 7 months) was
evaluated for changes in learning and memory with the
Morris water maze and fear-conditioning testing. All
three genotypes showed similar learning curves when
they tried to find a visible platform in the Morris water
maze (Figure S8A). When mice were retested 48 hr later,
NKO mice were significantly faster than control mice at
finding a hidden (submerged) platform that had been
moved to the opposite quadrant (NKO mice ¼ 42.3 5
9.3 s versus control mice ¼ 80.3 5 6.7 s, p < 0.001), but
only on the first trial with the hidden platform (Figures
S8B and S8C). Thereafter, learning curves for the hidden
platform were similar among the three genotypes
(Figure S8B). When mice were tested with a probe trial
7 days later, no difference in long-term memory was
observed (Figure S8D).
Mice were then tested in a contextual fear-conditioning
task, wherein the mice were placed into a novel environ-
ment and given an electrical foot shock to induce fear
memory, as demonstrated by behavioral freezing. NKO
mice showed reduced freezing behavior in response to a
foot shock (at 240 s, NKOmice¼ 8.2%5 5.1% versus con-
trol mice¼ 41.4%5 5.8%, p< 0.001; Figure 4C), and both
NKO mice and conditional heterozygous Deaf1þ/fl;Nes-cre
mice displayed significantly reduced contextual fear
memory 24 hr later (NKO mice ¼ 5.0% 5 2.3% and
Deaf1þ/fl;Nes-cre mice ¼ 24.6% 5 7.7% versus control
mice ¼ 40.9%5 4.2%; Figure 4D). Given that individuals
with de novo mutations in DEAF1 showed increased pain
tolerance, a potential explanation for the response in fear
conditioning might be a reduced ability to feel the foot
shock. However, relative to controls, NKO mice did not
display diminished responses to increasing levels of foot
shock (Figure S9).Discussion
Novel sequencing techniques have identified de novo mu-
tations in candidate genes for genetically heterogeneous
disorders such as ID. Correlating the clinical consequence
of such mutations in these candidate genes is, however,
challenging and relies on the identification of additional
individuals with mutations affecting the same gene and
an overlapping phenotype and functional assays. Here,
we describe de novo missense mutations affecting the
SAND domain of DEAF1 in four individuals with ID, severe
speech impairment, and behavioral problems. We showed
that all four of the amino acid substitutions impaired the658 The American Journal of Human Genetics 94, 649–661, May 1, 2normal function of DEAF1 in transcriptional regulation
of the DEAF1 promoter and produced loss or greatly
reduced binding of DNA ligands. Furthermore, we ob-
served that DEAF1 was highly expressed in the CNS and
that neuronal knockout of Deaf1 in mice resulted in
increased anxiety and deficits in learning and memory.
In this way, we have provided further evidence of a
causal role for de novo mutations affecting the SAND
domain of DEAF1 in the phenotype observed in these
individuals.
The phenotype of the individuals withDEAF1mutations
consisted of moderate to severe ID, disproportionally
severely affected expressive speech (but significantly better
speech comprehension and motor development), and
behavioral problems. Two of the four subjects were identi-
fied in preselected cohorts of individuals with moderate to
severe ID.2,4 The other two subjects, however, were identi-
fied in a cohort of over 2,300 individuals with unexplained
ID (an unselected cohort with the full phenotypic spec-
trum of individuals with ID), indicating that the ascertain-
ment of these latter individuals was not subjected to
selection bias. Because large-scale resequencing efforts
have only focused on high-quality variant calls, potentially
leaving some true mutations undetected, the true inci-
dence of DEAF1 mutations affecting the SAND domain of
DEAF1 in an unbiased cohort of individuals with ID re-
mains to be determined.
Angelman syndrome (MIM 105830) was considered in
the differential diagnosis for all four individuals on the
basis of their severely impaired speech development,
happy predisposition, fascination with water, and coordi-
nation problems, but a diagnostic methylation study of
the 15q11–q13 region and/or mutation analysis of
UBE3A (MIM 601623) gave normal results. In addition,
all four individuals were susceptible to recurrent infec-
tions, which might be explained by the role of DEAF1 in
interferon b gene transcription through interaction with
interferon regulatory factor 3.31 The behavioral abnormal-
ities present in three of the four individuals consisted of
autistic, hyperactive, and aggressive behavior with striking
mood swings. Because DEAF1 has previously been linked
to major depression and suicide through regulation of
5-hydroxytryptamine receptor 1A,20–22 disturbance of the
serotonin pathway might contribute to the phenotypes
seen in the individuals reported here. Interestingly, in
addition to the DEAF1 mutation in the second individual,
other candidate mutations were identified. The overlap-
ping phenotype between this girl and the other individuals
with mutations in DEAF1 indicates that the mutation in
DEAF1 is the underlying cause.
We observed a high expression of DEAF1 mRNA in the
CNS in both humans and mice, as well as in zebrafish.
This expression was observed in both fetal and adult hu-
man brain, whereas in zebrafish, deaf1 expression was
highest at earlier developmental stages. Deaf1 has been
previously reported to be widely expressed in mouse and
rat tissues, as well as highly expression in the CNS.6,32,33014
The expression of DEAF1 at the high level found in the
CNS might explain why mainly the nervous system is
affected in these individuals.
We aimed to determine whether the different amino
acid substitutions observed in the individuals with ID
compromised normal functioning of DEAF1. All four
de novo mutations altered the SAND domain, suggesting
that these might result in inappropriate functioning of
this domain. We tested the effect of the amino acid substi-
tutions on three essential functions of the SAND domain,
namely DNA binding, transcription regulation, and
SAND-domain-mediated protein interactions. All four sub-
stitutions showed loss of transcriptional repression of the
DEAF1 promoter, indicating that all mutations identified
in this study impair the normal function of DEAF1 in tran-
scriptional repression. In addition, three of the substitu-
tions showed complete loss of DNA binding, and one
showed greatly reduced DNA binding. Three of the four
amino acid substitutions failed to activate the Eif4g3 pro-
moter, and two of them even resulted in a 10-fold suppres-
sion of transcription relative to basal expression levels.
Three of the four substitutions also resulted in reduced
interaction with XRCC6, indicating that for these substitu-
tions, SAND domain function seems further compromised.
The impaired repression of the DEAF1 promoter indi-
cates that the de novo mutations as seen in these individ-
uals could impair the normal function of DEAF1 by a
loss-of-function effect. Contradictory to this hypothesis,
however, is the observation that deletions including
DEAF1 have been reported for healthy controls34 and
that we identified a 1 bp insertion (chr11: g.674717del)
leading to a frameshift (p.Leu441Trpfs*16) in DEAF1 in a
healthy individual (data not shown). Therefore, a more
likely mechanism explaining the consequences of these
DEAF1 mutations might be a dominant-negative effect.
Data that support this hypothesis are that all of the altered
forms of DEAF1 were able to interact with a cytoplasmi-
cally localized DEAF1 and relocalize it to the nucleus and
that two of the altered proteins produced dominant-nega-
tive activity in the transcriptional activation of Eif4g3. In
previous large-scale exome sequencing studies, the impor-
tance of loss-of-function mutations was stressed,35,36 but
here we show the importance and clinical relevance of
missense mutations most likely caused by effects different
from loss of function.
Because the de novo mutations identified in individuals
with ID most likely have dominant-negative activity, inca-
pacitating both copies of DEAF1, we hypothesized that
knockout of Deaf1 in mice would result in behavior disor-
ders. To test this hypothesis, we produced mice with a tar-
geted disruption of Deaf1. Because our full knockout of
Deaf1 was embryonically lethal, we utilized a conditional
knockout of Deaf1 in the brain to perform studies on large
enough cohorts of mice to obtain behavioral data. Partial
survival of another Deaf1-knockout mouse was previously
reported.18 The increased lethality in our knockout mice
could be due to strain differences, or the other mouseThe Ammodel could represent mice with partial retention of
Deaf1 function.
Mice with conditional homozygous knockout of Deaf1
in neuronal tissues showed increased anxiety in the EPM
and the open-field test. The increased anxiety behavior of
the NKO mice might be relevant to the behavioral abnor-
malities observed in individuals with de novo DEAF1 mu-
tations. Fear-conditioning tests demonstrated a deficiency
of NKO mice to freeze in response to foot shock, which
additional testing indicated was unlikely to be due to
diminished pain sensitivity, inferring that it might be
related to an increased anxiety response of the mice.
Compared to WTmice, both NKO and conditional hetero-
zygous mice showed a lack of contextual memory in the
fear-conditioning test after 24 hr. The memory deficits in
the NKOmice might have relevance to higher-order cogni-
tive deficiencies of individuals with ID. The observation
that conditional heterozygous knockout mice also had
memory deficits provides supporting evidence that the
de novo DEAF1mutations observed in these heterozygous
individuals might result in ID.
In conclusion, we show that de novo mutations
affecting the SAND domain of the transcription factor
DEAF1 cause a human phenotype characterized by ID
with severe speech impairment and behavioral problems
and provide various functional evidence that links dysre-
gulation of DEAF1 to the observed phenotype. Over the
coming years, we expect many more mutations in DEAF1
to be identified. Therefore, we established a website to
collect detailed phenotypic data of individuals harboring
DEAF1mutations not only to gain insight into the clinical
spectrum that these mutations might cause but also to
obtain fundamental understanding of the pathogenic
mechanisms underlying DEAF1-related ID.Supplemental Data
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